Deals In Depth: September 2015

AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.

Exhibit 3

Financings By Type ($m)

More from Deal-Making

More from In Vivo